Clinical Trial Update: Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial updating targeted therapy with lapatinib in recurrent pituitary tumors resistant to standard therapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Adenomas
• Prolactinomas

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Pituitary Adenomas, Prolactinomas | Phase 2 | Status: COMPLETED | Results posted: 2020-01-13